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ABSTRACT 
Generation of a Cytomegalovirus Expressing Interleukin-12 to Study Viral Dissemination and 
Immunogenicity in the Guinea Pig Model. (May 2014)  
 
Sarah Kate Maddux 
Department of Science 
Texas A&M University 
 
Research Advisor: Dr. Alistair McGregor 
Department of Microbial Pathogenesis & Immunology 
 
Congenital cytomegalovirus (CMV) is a leading cause of mental retardation and deafness in 
newborns; therefore, the development of a vaccine for the virus is of great importance. The 
guinea pig is the only small animal model for the study of congenital CMV infection and since 
HCMV and other CMV are highly specific to particular host species, guinea pig CMV 
(GPCMV) must be used for congenital CMV infection studies. Interleuking-12 (IL-12) is a 
proinflammatory cytokine dimer that stimulates T-cell activity during the immune response. The 
subunits of IL-12, especially the IL-12p40 (IL-12B) subunit, have potential for use as adjuvants 
in CMV vaccines to stimulate the T-cell response. The purpose of this project is to use molecular 
cloning strategies to create recombinant guinea pig CMV (GPCMV) strains expressing the 
guinea pig ortholog of IL-12B. This will allow the investigation of the effect of the IL-12B 
subunit on CMV pathogenicity in the guinea pig animal model as well as the impact of this 
cytokine on the resulting T-cell immune response to GPCMV infection.  
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CHAPTER I 
INTRODUCTION 
The Herpesviridae virus family is composed of enveloped, icosahedral, double-stranded DNA 
viruses classified in three subfamilies: alpha, beta, and gamma [Knipe & Howley, 2013]. 
Herpesviruses are characterized by their ability to establish latency during infection, remaining 
in the host’s system for the duration of the organism’s life. During latency, the virus’s genome is 
maintained in virtually dormant episomes after primary infection until circumstances are optimal 
for reactivation of infection [Knipe & Howley, 2013]. There are eight different human 
herpesviruses (HHV1-8) that cause a variety of diseases and establish latency in different parts of 
the body. 
Cytomegalovirus (CMV) is a betaherpesvirus and like most herpesviruses, it has a relatively 
large genome; the human cytomegalovirus (HHV-5, HCMV) genome is the largest of any 
herpesvirus at 236,000 bp (Figure 1). It is spread by direct contact with body secretions such as 
saliva and sexual contact [Knipe & Howley, 2013]. It disseminates quickly in the host and 
establishes latency, but is usually asymptomatic because the host immune system suppresses the 
infection to low levels [Knipe & Howley, 2013]. However, the virus is opportunistic and when 
the host immune system is compromised for any reason, such as in transplant patients and HIV-
infected individuals, it can cause a variety of life-threatening end organ diseases [Knipe & 
Howley, 2013]. It is also the most common congenital viral infection and the leading cause of 
neurological sequelae, mental retardation, and deafness in newborns [Knipe & Howley, 2013]. 
The rate of infected newborns is about 1%, though it varies by region and population and can 
range up to 2% [Kenneson & Cannon, 2007]; this transmission rate can increase due to a variety 
of risk factors, such as HIV exposure and premature delivery [Kenneson & Cannon, 2007]. 
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Transmission rates from mothers with a primary HCMV infection is about 32%, while congenital 
infection from a maternal latent infection is much lower [Kenneson & Cannon, 2007]. 
Approximately 10% of congenitally infected infants exhibit symptoms [Kenneson & Cannon, 
2007]; of those infants, 90% suffer from mental, hearing, visual, or motor disabilities apparent at 
birth, though some of these same symptoms may manifest later in life in initially asymptomatic 
children [Ghekiere et al. 2012]. This means that over 5000 children born every year suffer from 
serious medical conditions due to congenital HCMV infection, creating a long-term public health 
concern (Figure 2). A review panel at the Institute of Medicine declared that a vaccine to protect 
pregnant women from HCMV infection in order to prevent congenital infection was second in 
priority only to an HIV vaccine in the field of infectious disease [Stratton et al. 2000].  The same 
study estimated that an effective HCMV vaccine would save up to $4 billion annually in the U.S. 
 
Figure 1. The general structure of the HCMV virion. [Reddehase, 2006] 
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However, efforts to produce an effective 
HCMV vaccine have been only partially 
successful. Over the past several decades, 
much time and effort has been expended in 
trying to develop various vaccine strategies, 
such as protein subunit, aphavirus replicons, 
and attenuated live vaccines [Lilja & Mason, 
2012]. Many have focused on the 
neutralizing antibody response to the gB 
fusion protein [Lilja & Mason, 2012]. In 
fact, phase 2 clinical trials have been 
conducted to test the efficacy of a purified 
gB vaccine combined with the MF59 
adjuvant, but the vaccine was found to be 
only 50% effective in protecting against 
primary HCMV infection [Pass et al. 2009]. Other studies have explored using T-cell targets 
such as the protein pp65 with some success in mounting a T-cell response, and though several 
vaccines have undergone clinical trails, no vaccine has shown enough clinical protection from 
HCMV to be approved for use [Lilja & Mason, 2012]. Further research is necessary to increase 
the efficacy of current vaccine strategies or develop more effective ones. A robust T-cell 
response to viral antigens is important for controlling life-long infections in convalescent HCMV 
patients. The endeavor to develop an effective vaccine not only includes the study of the 
antibody response and T-cell response to viral antigens; various adjuvants are being considered 
Figure 2. HCMV epidemiology statistics. 
Over 5000 children born each year suffer from 
long-term medical conditions because of 
congenital HCMV infection, more than any 
other condition.  
Source: Center for Disease Control  
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in an effort to increase the efficacy of the vaccine [Chen et al. 2013]. Additionally, though the 
most common type of vaccine stimulates a humoral (antibody-mediated) immune response, 
stimulating the specific T-cell response to infection may also have great potential as a vaccine 
strategy.  
 
The multicomponent immune response to HCMV infection is complex and incompletely 
understood. The primary targets for neutralizing antibodies are the viral envelope glycoproteins 
gB and gH and antibodies against various other glycoproteins and glycoprotein complexes have 
been detected [Knipe & Howley, 2013]. However, it appears that the antibody response is not 
enough to protect against HCMV infection, because seropositive individuals can often be 
reinfected [Ross et al. 2010]. The cytotoxic T-cell response appears to be more crucial to HCMV 
protection, as evidenced by the severe HCMV secondary infections that occur in T-cell deficient 
AIDS patients [Lilja & Mason, 2012]. The highly abundant tegument protein pp65 is a common 
CD8+ T-cell target, as is the IE1 protein, which is expressed soon after infection [Gibson et al. 
2004], but there may be other uncharacterized T-cell targets. Stimulating and maintaining a T-
cell response to HCMV infection will likely be an important part of any successful vaccine 
strategy, and continued research is being conducted to develop delivery systems and adjuvants to 
do so [Lilja & Mason, 2012].  
 
Interleukin-12 (IL-12) is an important proinflammatory cytokine produced by dendritic cells and 
phagocytes in response to recognition of pathogens by Toll-like receptors and other receptors 
[Chang & Radbuch, 2007]. Like all cytokines, this protein dimer is a secreted glycoprotein that 
interacts with receptors on nearby cells to regulate their gene expression and behavior [Shrum, 
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1996]. Interleukins in particular play an important role in regulating immunity, including 
stimulating T-cell proliferation and inducing fever [Shrum, 1996]. Interleukin-12 plays several 
roles in the immune response; it activates natural killer cells [Brunda, 1994], induces interferon-γ 
production, and is thought to be imperative for the development and proliferation of the Th1 T-
cell immune response by stimulating production of IFN-γ [Chang & Radbuch, 2007]. 
Effectively, it acts as a link between the innate and adaptive immune system [Trinchieri, 2003].  
 
Mature Th1 regulatory cells induced by IL-12 produce Interleukin-10 (IL-10) some time after the 
immune response is induced, providing a negative feedback mechanism to regulate the immune 
response [Chang & Radbuch, 2007]. This cytokine can limit the T-cell response during CMV or 
other viral infections, though it also stimulates the Natural Killer (NK) cell response to infection 
[Stacey et al. 2011]. It has been found that HCMV encoded an IL-10 homolog that exhibits the 
immunosuppressive functions of IL-10, but not its immunostimulatory activities [Kotenko et al. 
2000]. This ability allows the virus to suppress IL-12 activity and avoid the T-cell mediated 
immune response [Kotenko et al. 2000]. 
Upregulating IL-12 expression or 
downregulating IL-10 expression may 
counter this evasion tactic.  
 
 
 
 
Figure 3. Structure of the human IL-12 
dimer. The blue subunit is IL-12B and the red 
subunit is IL-12A. Source: Protein Database, 
rcsb.org 
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IL-12 consists of two subunits, designated p35 (IL-12A) and p40 (IL-12B); the p40 unit is shared 
with IL-23, but the p35 unit is unique to IL-12 (Figure 3) [Chen et al. 2013]. The cytokine has 
been shown to act as an effective adjuvant in vaccination for rhesus macaque CMV [Jacobson et 
al. 2006], but use of both subunits simultaneously may have cytotoxic effects in humans and has 
actually suppressed the immune response in mice [Leonard et al. 1997, Orange et al. 1995]. It 
has been suggested that the two subunits play different roles in the immune response [Osario & 
Ghiasi, 2005] and when administered individually, both subunits have been shown to have the 
ability to stimulate an immune response. However, there is some controversy about which 
subunit can more effectively do so. One study showed that IL-12A increased the efficacy of the 
immune response against HSV-1 in a recombinant viral vaccine [Osario & Ghiasi, 2005], but a 
study by Chen [Chen, et al. 2013] indicated that IL-12B is more important in stimulating an 
immune response to Chlamydia muridarum and a study conducted by Khader et al. showed that 
IL-12B is essential for immunity to Mycobacterium tuberculosis [Khader et al. 2006]. The 
subunits of this potent cytokine may be useful as adjuvants for a recombinant CMV vaccine, but 
further research is necessary to determine the full extent of the relative effects of each subunit. 
 
As with many other infectious diseases, the use of animal models has proven invaluable in the 
study of HCMV. Guinea pigs offer the only practical animal model for congenital CMV 
infection studies. Guinea pig CMV (GPCMV) produces many of the same defects in newborn 
pups as appear in infected newborn humans [Hashimoto et al. 2013]. HCMV and GPCMV are 
very similar; most HCMV genes have homologs in GPCMV (Figure 4).  
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Importantly, many guinea pig cytokines have been cloned into cDNA and characterized at Texas 
A&M and other institutions, including the guinea pig ortholog of IL-12 [Shiratori et al. 2001]. 
The protein sequence and structure of guinea pig IL-12 (gpIL-12) are similar to that of human 
IL-12 and the cytokine performs the same functions [Shiratori et al. 2001]. This makes GPCMV 
an important model in which to study the effect of IL-12 on the host immune response to CMV 
infection. 
  
 
 
 
 
Though there is some controversy over which component of IL-12 is most important to the 
immune response during infection, a majority of the literature indicates that IL-12B may be more 
effective at stimulating the T-cell response [Chen et al. 2013, Khader et al. 2006]. With that in 
mind, the goal of this project was to create a recombinant GPCMV virus encoding gpIL-12B in 
order to investigate the effect of IL-12B on the T-cell response during CMV infection in future 
experiments. Elucidating the role of IL-12B in this context will inform the possibility of its use 
as a vaccine adjuvant to stimulate the T-cell response. 
	  
	  
Figure 5. Homology between HCMV and GPCMV genomes. Most genes in HCMV 
have a homolog in GPCMV [McGregor et al. 2013]. 
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Figure 6. Human and guinea pig IL-12 protein alignments. A BLAST alignment 
comparing the protein sequences of human and guinea pig IL-12 subunits. IL-12A (top) 
shows 78% identity (identical amino acids) and 86% positivity (similar amino acids). 
IL-12B (bottom) shows 76% identity and 84% positivity.  
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CHAPTER II 
METHODS 
Restriction digests, gel electrophoresis, & DNA isolation 
To isolate DNA fragments, confirm cloning results, or analyze BACs, digestions were carried 
out with restriction enzymes in appropriate buffers according to manufacturer protocol. The 
digested DNA was applied to an agarose gel and the DNA fragments separated by gel 
electrophoresis. The GeneClean® II (Obiogene) kit was used to purify DNA fragments from the 
gels when necessary. Briefly, the gel slices were dissolved in 1.5 mL of 6 M sodium iodine 
solution and 15 µL glassmilk was added to bind DNA. The glassmilk beads were washed three 
times with the GeneClean® II NEW wash buffer and the DNA was eluted from the glassmilk in 
20 µL DNase/RNase-free water by centrifugation in a microcentrifuge at 15,000 rpm.  
 
Gene cloning and transformation 
Vector cloning was carried out by using T4 ligase to ligate restriction-digested DNA fragments 
into vectors digested with a compatible restriction enzyme. The ligations were either performed 
in a 10X ligation buffer overnight at 14˚C or in a 2X Quick ligation buffer followed by a 15-
minute incubation at room temperature, using amounts of vector proportional to the amount of 
insert DNA. The ligations were transformed into DH5α bacterial cells using a one-minute heat 
shock at 42˚C followed by a 30-minute incubation on ice and a one hour incubation in 1 mL LB 
media at 37˚C, shaking at 100 rpm. The transformations were grown on agar plates at 37˚C with 
appropriate antibiotic selection. Colonies were then inoculated into 2 mL LB cultures under 
antibiotic selection and grown overnight at 37˚C, the plasmid DNA purified with a Qiagen 
plasmid miniprep kit, and analyzed by restriction enzyme digest analysis.  
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Polymerase Chain Reaction (PCR) 
DNA was amplified using Vent DNA polymerase. All PCR was carried out according to the 
parameters in Table 1. All oligonucleotides were synthesized by Sigma-Genosys (The 
Woodlands, TX). 
 
Number of Cycles Temperature Duration 
1 97˚C 3 minutes 
35 
97˚C 30 seconds 
56˚C 30 Seconds 
72˚C Variable: 30 seconds per  500 bases 
1 72˚C 5 minutes 
Table 1. Parameters for PCR Reactions. The same parameters were used for all PCR 
reactions, with 35 cycles and the extension stage varying according to the size of the template 
(30 seconds per 500 bases). 
 
Generation of Electrocompetent Cells  
An inducible recombination system (ET system) plasmid was transformed into DH10B bacterial 
cells containing the GPCMV bacterial artificial chromosome (BAC) plasmid and plated under 
chloramphenicol selection. The cells were cultured in 10 mL LB media overnight shaking at 
37˚C under chloramphenicol selection (15 µg/mL) and then in 500 mL LB at 30˚C, shaking at 
300 rpm for 4 hours under chloramphenicol selection. The culture was placed in a 37˚C water 
bath for fifteen minutes. L-Arabinose was added (0.1% final concentration) from a stock solution 
of 20% (w/v) to the culture and incubation in the 37˚C water bath continued for another 10 
minutes. The culture was then incubated in an ice slurry for one hour to induce ET expression. 
The culture was centrifuged at 5000 rpm at 4˚C, the supernatant decanted, and the pellet 
resuspended in 500 mL ice cold distilled water. The solution was centrifuged at 6000 rpm at 4˚C 
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for 20 minutes, the supernatant decanted, and the pellet resuspended in 250 mL cold distilled 
water. The centrifugation was repeated twice, the pellet being first resuspended in 100 mL cold 
distilled water and then in 10 mL ice cold 10% glycerol. The suspension was aliquoted into 
chilled microcentrifuge tubes, centrifuged at 6000 rpm for 1 minute, the supernatant poured off, 
and the pellets resuspended in ten 300 µL aliquots of 10% glycerol. The cells were then stored at 
-80˚C until use.  
 
BAC Recombination  
Vectors containing the DNA constructs of interest were recombined with GPCMV BACs 
contained in electrocompetent cells. The DNA was mixed with the ET cells in a microcentrifuge 
tube on ice and then transferred to a chilled cuvette before electroporation. The cells were 
incubated at 37˚C for several hours before plating on agar plates under chloramphenicol 
selection (for the BACs) and the appropriate antibiotic for the construct recombined into the 
BACs.  
Colonies were inoculated into 2 mL starter cultures and then 500 mL cultures of double 
antibiotic LB media (chloramphenicol and antibiotic marker selecting for introduced DNA) and 
the BACs purified by large scale prep with a Qiagen maxiprep protocol modified for BACs.  
Restriction enzyme digest analysis was used to analyze the restriction profile of the BACs in 
comparison to wildtype.  
 
Guinea pig cell transfection and tissue culture  
The purified BACs were transfected into guinea pig fibroblast lung cells (GPL; ATCC CCL 158) 
using Lipofectamine 2000 (Invitrogen) following manufacturer protocol. All transfection 
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procedures were conducted in a biosafety hood. In a total volume of 200 µL of OPTIMEM media 
(Invitrogen), 30 µL of the BAC DNA was mixed with 2 µL of the Lipofectamine and incubated 
at room temperature for 10 minutes. The BAC solution was then added to 6-well dishes 
containing GPL cells and 1 mL of OPTIMEM media. The GPL cells had already been washed 
with 2 mL of OPTIMEM. The dish was incubated at 37˚C for three hours, the wells washed with 
2 mL PBS, and then covered with 4 mL of F-12 media (Invitrogen/Gibco-BRL) supplemented 
with 10% fetal calf serum (FCS; Gibco-BRL), 10,000 IU of penicillin/liter, 10 mg of 
streptomycin/liter (Gibco-BRL), and 7.5% NaHCO3 (Gibco-BRL). The dishes were kept at 37˚C 
and the F-12 media changed twice on the day after transfection and then once per day for four 
days after that.  
The cultures were monitored by fluorescent microscopy for GFP expression and development of 
GFP-tagged GPCMV. 
 
FLP-FRT Recombination 
To remove an antibiotic marker flanked by FRT sites, FLP-FRT recombination was performed 
with the tetracycline-resistant 707-FLPe plasmid (Genebridge) according to manufacturer 
protocol. Briefly, the 707-FLPe plasmid was transformed into bacterial cells already containing a 
BAC as described, plated on LB agar plates under antibiotic selection (tetracycline, 
chloramphenicol, and the resistance marker for the recombined DNA), and grown for 24 – 48 
hours at 30˚C. Colonies were inoculated from these plates into 1 mL LB cultures supplemented 
with chloramphenicol and tetracycline and incubated 2 – 3 hours at 30˚C and shaking at 300 
rpm. The temperature was increased to 37˚C for 3 hours, still shaking at 300 rpm. An inoculation 
loop was used to streak out cultures on LB plates supplemented with chloramphenicol and 
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incubated at 37˚C overnight. Resulting colonies were patch plated first on plates supplemented 
with chloramphenicol and the antibiotic selecting for the DNA modification and then on plates 
containing only chloramphenicol. The plates were incubated overnight at 37˚C. Colonies were 
selected that showed growth on the chloramphenicol plates but not the plates supplemented with 
the antibiotic selecting for the DNA modification; these were cultured under chloramphenicol 
selection and purified by large scale prep.  
 
Virus Titration & Growth Curve 
Recombinant GPCMV virus-infected GPL cells and supernatant (input virus multiplicity of 
infection (MOI): 1 PFU/cell) were harvested from six-well dishes every day post infection for 
seven days and stored at -80˚C until use. The viral supernatant was serially diluted to a 10-6 
dilution and 100 µL of each dilution used to infect GPL cells. After four days, viral plaques were 
counted and plaque-forming units (PFU) per mL calculated. The results were plotted (PFU/mL 
versus time) on a semi-logarithmic plot.  
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CHAPTER III 
RESULTS 
Recombination System Testing 
To ensure that the BAC recombination system would work properly for our purposes, we created 
a GP75 knock out BAC. The GP75 gene encodes guinea pig gH, a glycoprotein presumed to be 
essential for cell entry in HCMV [Paradowska et al. 2014], making the knock-out lethal. We 
recombined a version of the GP75 with a portion of the gene deleted as an NruI/EcoRV fragment 
and replaced with a kanamycin resistance marker (Suppl. Fig 1). The restriction profile of the 
resulting BAC was analyzed by restriction digestion with EcoRI and HindIII (Figure 7). The 
BAC was transfected into GPL cells to ensure lethality of the knock out (Figure 8a). Then it was 
co-transfected with a plasmid expressing gH to rescue the phenotype, confirming the cause of 
lethality as the knocked out GP75 gene (Figure 8b).  
 
Cloning Shuttle Vector Construction 
Part of the coding sequence of the GP25/26 locus was amplified by PCR with EcoRI sites 
incorporated at the 5’ and 3’ ends (Suppl. Fig. 2) because there is an endogenous BamHI site in 
the intergenic region that can be used for cloning. These were used to insert the GP25/26 gene 
complex into the multiple cloning site (MCS) of the pUC19 vector, which contains an ampicillin 
resistance marker (Suppl. Fig. 3). A HindIII digestion was used to linearize the DNA so the 
clones containing the modified vector could be easily identified (Figure 9).  
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Figure 8. GPCMV gH knock out recombinant BAC transfections. (A) When transfected 
onto GPL fibroblast cells, the GFP signal could be detected in transfected cells, but the virus 
did not disseminate to other cells. (B) When the GPCMV gH knock out BAC was co-
transfected with a plasmid carrying the wildtype GP75 locus, a rescued virus was generated 
through recombination that was able to disseminate through the monolayer.  
Figure 7. Restriction enzyme analysis of gH knock out recombinant BACs. (A) EcoRI 
digestion of wildtype GPCMV BAC (Lane 1) versus knock out recombinant BACs (Lanes 2 & 
3). Due to the deletion in the gene, an EcoRI is missing in the recombinant BACs, causing the 
presence of a new 38 kb band instead of a 20 kb and an 18 kb band. (B) HindIII digestion of 
wildtype (Lane 1) versus recombinant BACs (Lanes 2 & 3). The introduction of a new HindII site 
in the kanamycin cassette causes two new bands at 26 kb and 18 kb instead of the large one at 44 
kb. This result confirms the successful recombination of the modified GP75 gene construct. (C) 
GPCMV BAC maps. The top part of the figure shows the restriction profile of a wildtype 
GPCMV BAC. The lower part of the figure shows the modified profile, with a new HindIII site 
inserted and an EcoRI site deleted. 
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The SV40 promoter and polyadenylation sequences were digested out of a pSI vector (Suppl. Fig 
5) as a BglII/BamHI fragment and inserted into the endogenous BamHI site between the GP25 
and GP26 genes (Suppl. Fig. 4). Orientation of the insertion was determined by HindIII digestion 
(Figure 10). The intron downstream of the SV40 promoter and most of the MCS were collapsed 
by a PstI/SalI digestion and the SV40 multiple cloning site (MCS) modified to include an XhoI 
site (Suppl. Fig. 6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. HindIII digestion of the pUC19/GP2526 vector. Ten clones were analyzed 
by HindIII digestion to determine whether the GP25/26 construct had been inserted into 
pUC19 vector. In clones 3, 7, 9, and 10, the 4.0 kb band size indicates the presence of 
the 1.3 kb insert into the 2.7 kb vector. 
Figure 10. HindIII digestion of the pGP2526 + SV40 vector. There is a HindIII site 
immediately after the 0.4 kb SV40 promoter, allowing orientation of insertion to be 
determined. The clones that exhibit the 1.0 kb band (1, 2, 5, 7, 9, 10) are inserted so that 
expression will occur in the same direction as the GP25 gene. This was the orientation 
chosen for the next cloning experiments. Clones 4 and 6 exhibit a 0.9 kb band and have the 
SV40 construct inserted so that expression will occur in the same direction as the GP26 
gene.  Clone 3 does not contain the SV40 insert at all. The lane on the far right contains a 
sample of undigested vector (clone 1) for comparison.  
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Hygromycin Marker Cloning Strategy 
The initial cloning strategy involved the use of a hygromycin marker to supply antibiotic 
selection that would stabilize the presence of the gpIL-12B gene in the virus. The gene for the 
resistance marker hygromycin was amplified by PCR. BamHI sites were incorporated into the 3’ 
and 5’ ends using primers and inserted into the BamHI site downstream of SV40 polyadenylation 
signal (Suppl. Fig. 7), allowing hygromycin selection of the construct. To ensure insertion and 
determine orientation of insertion, BamHI and EcoRI digests were performed (Figure 11).  
 
 
 
 
 
 
 
 
Figure 11. Restriction digests of the cloning vector containing hygromycin 
resistance marker. (A) BamHI digestion confirms insertion of hygromycin resistance 
cassette into all clones (1.7 kb band). (B) EcoRI digestion indicates which orientation 
the cassette inserted into the vector in each clone. In clones 1 – 3, the cassette inserted 
so that expression would occur in the same direction as the GP25 gene and clones 4 – 6 
indicate that the cassette inserted so that expression would occur in the same direction as 
the GP26 gene. The first orientation (clones 1 – 3) was chosen for future cloning steps.  
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Generation of a Recombinant GPCMV Encoding a Hygromycin Resistance Marker  
To ensure that it would not have an effect on virus growth kinetics, the cloning construct 
containing the hygromycin resistance cassette was recombined into a GPCMV BAC. The 
resulting BACs were analyzed by restriction enzyme digest analysis (Figure 12) and a full-length 
BAC was transfected into GPL cells, producing a replicating virus (Figure 13). 
A multi-step growth analysis was performed to establish growth kinetics and the results are 
shown in Figure 14. The growth kinetics of the virus appear to follow a normal pattern, 
exhibiting characteristic growth followed by plateau at later timepoints when most of the cell 
monolayer has been destroyed by the virus. This indicates that the shuttle construct will not 
impair the dissemination of the virus in cell culture.  
 
 
 
 
 
 
Figure 13. GFP+ 
recombinant 
GPCMV. The 
recombinant BAC 
containing the 
modified GP25/26 
locus was 
transfected onto 
GPL cells and the 
resulting 
fluorescent virus 
imaged and 
harvested.  
Figure 12. EcoRI restriction digestion of recombinant BAC 
containing cloning construct with a hygromycin resistance 
marker. (A) GPCMV BAC map showing the insertion of a new 
EcoRI site into the GP25/26 locus. (B) The modified EcoRI 
restriction profile of the recombinant BAC showing a new band 
at 3.4 kb. The other larger new band is obscured by already 
existing bands. 
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To ensure that the genes introduced into the GP25/26 locus would express properly, we treated a 
monolayer infected with the resulting recombinant virus with hygromycin at a concentration of 
100 ng/mL two days after infection. This antibiotic inhibits protein synthesis and was expected 
to kill any eukaryotic cells not infected with the virus carrying the hygromycin resistance gene. 
Two days after treatment, much of the monolayer had been decimated but intact cells expressing 
the GFP signal indicating viral infection could still be detected. This indicates that the 
recombinant virus is causing expression of the hygromycin resistance gene (Figure 15). 
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Figure 14. Growth kinetics of a recombinant GPCMV virus encoding a hygromycin 
resistance marker. The recombinant virus containing the modified GP25/26 locus was used to 
infect GPL cells and the supernatant and cell solution was harvested daily for seven days post 
infection. Titrations were performed and the resulting PFU/mL plotted on a semi-logarithmic 
plot. The growth kinetics exhibited by the recombinant virus appear normal relative to the 
characteristic growth of GPCMV.  
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Kanamycin Marker Cloning Strategy 
It was unknown what long-term effect the hygromycin resistance marker might have on the 
stability of a recombinant virus in cell culture, so for the creation of a BAC expressing only 
gpIL-12B, a second cloning strategy was employed that does not require that an antibiotic 
Figure 15. Recombinant GPCMV grown in the presence of hygromycin. (A) GPL cells 
infected with wildtype GPCMV. (B) When hygromycin (100 ng/mL) was added to the 
monolayer infected with the wildtype virus, the cells died and the GFP signal was almost 
completely lost. (C) GPL cells infected with recombinant GPCMV encoding the 
hygromycin resistance gene. (D) When hygromycin was added to the monolayer infected 
with the recombinant GPCMV, the infected cells survived and the GFP signal was fully 
preserved.  
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resistance marker to be present in the recombinant BAC. First, gpIL-12B was synthesized by 
PCR with primers that incorporate XhoI sites into the 3’ and 5’ ends. It was ligated into the 
pLitmus128 vector and transformed under kanamycin selection. The gpIL-12B shuttle vector 
was purified from culture by large-scale prep, the IL-12B gene was excised by XhoI digestion, 
and it was inserted into the XhoI site of the shuttle vector containing GP25/26 and the SV40 
genes (Suppl. Fig. 8). An XhoI digestion was performed to establish insertion of the gpIL-12B 
gene and EcoRI and HindIII digestions were performed to establish orientation of insertion in 
each clone (Figure 16). It was important that the gene be inserted in the same orientation as the 
SV40 promoter and polyadenylation sequence.  
A kanamycin FLP-FRT recombinase cassette was inserted as a BamHI fragment into the BglII 
site of the gene construct, between the SV40 promoter and the gpIL-12B sequence (Suppl. Fig. 
9). Insertion and orientation of insertion was determined by digestion with HindIII (Figure 17). 
This construct was amplified by PCR, purified by gel electrophoresis, and recombined into a 
GPCMV BAC.  
After recombination, a FLP-recombinase was used as described to excise the kanamycin 
resistance marker from the BAC, leaving only the FRT sites and gpIL-12B in the modified 
GP25/26 locus (Suppl. Fig. 10).  
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Figure 16. Restriction digestion of shuttle vector containing gpIL-12B. (A) XhoI 
digestion confirms that all 10 clones analyzed have the 1.0 kb gpIL-12B insert. (B) 
BamHI digestion showing that clones 1, 2, 6, 8, and 10 have gpIL-12B inserted in the 
same orientation as the SV40 promoter, with bands at 4.7 kb and 0.9 kb The restriction 
profile of clones 3, 4, 5, 7, and 9 (5.1 kb and 0.5 kb) indicate that gpIL-12B inserted in the 
opposite orientation. (C) An EcoRI digestion confirmed the results of (B). The correct 
orientation has a profile of 3.7 kb, 1.2 kb, and 0.7 kb.   
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Two bacterial clones containing the recombinant BAC were cultured and purified in a large scale 
prep. However, when digested with EcoRI, the resulting BACs did not appear to be full length 
(Figure 18). Minipreps of 10 other clones containing 
the recombinant BAC were performed and digested 
with EcoRI, confirming that none contained a full-
length BAC. Recombination will have to be repeated or 
the strategy modified to obtain a full-length BAC 
containing IL-12B. 
Figure 17. HindIII digestion of gpIL-12B cloning vector containing a kanamycin 
resistance marker. The restriction profiles indicate that all 10 clones contain the 
kanamycin resistance cassette, but only clones 2, 4, 5, 9, and 10 exhibit the profile (3.9 kb, 
2.0 kb, and 0.7 kb) that indicate the cassette inserted in the same direction as the SV40 
promoter. A clone with this orientation was chosen for recombination into a BAC. 
Figure 18. EcoRI restriction profile of recombinant 
GPCMV BAC containing gpIL-12B. The two clones 
containing recombinant BACs (Lane 2 & 3) show an 
unusual restriction profile that indicates that the BAC does 
not contain the entire GPCMV genome.  
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CONCLUSION 
BAC Recombination System 
The successful creation of a gH knock out BAC shows that the use of recombinant BACs can be 
used to study viral gene function and develop recombinant viruses. The recombinant knock out 
BAC expressed GFP but did not produce any infectious virus because it was missing an essential 
gene. To ensure no additional secondary mutations occurred that would be lethal to the BAC, the 
knock out BAC was co-transfected with a rescue plasmid that restored the GPCMV mutant to 
wildtype. This showed that the gH knock out alone was responsible for the impairment of the 
virus. 
 
 This result concurs with current evidence; recombinant BACs have been used extensively in the 
past to create recombinant virus. Creating a recombinant virus directly is very difficult, time-
consuming, and often produces unexpected mutations in the viral genome. This method of 
generating recombinant virus is much quicker, easier, and more accurate [Dekhtiarenko et al. 
2014]. It produces the modification desired without introducing any other mutations, making it 
the perfect technique for creating a recombinant virus expressing gpIL-12B. 
 
GP25/26 Modified Locus 
Inserting DNA into the region between GP25 and GP25 should hypothetically not affect 
expression of the genes or the growth of the virus because the utilized BamHI site is in the 
intergenic region the genes co-terminate in this region. The results of inserting the hygromycin 
resistance cassette and SV40 genes confirm this result. The recombinant virus produced had 
normal growth kinetics, indicating that the added genes in the modified locus did not noticeably 
27	  
impair the virus. Additionally, the hygromycin resistance gene inserted into the locus was 
expressed well enough to provide resistance to hygromycin treatment at a level that wound 
normal kill the cells. The locus and the gene construct recombined into it appear to be an optimal 
environment for introducing a new gene to the GPCMV genome.  
 
Guinea pig IL-12B Cloning & Recombination 
The guinea pig IL-12B was successfully cloned into the shuttle vector, but there was an 
unidentified error in recombination, causing the production of BACs that contain only part of the 
GPCMV genome. It is possible that the gene or the kanamycin resistance cassette causes 
instability of the genome in the BAC. As it only adds 1 kb to the size of the BAC, it seems more 
likely that there was an error in the recombination procedure. The recombination should be 
repeated and the results analyzed. 
 
 If full-length GPCMV BACs cannot be produced with the described cloning strategy, the 
strategy will be modified. The hygromycin marker cloning strategy could be completed. Though 
it is unknown what long-term effects the resistance marker might have on the GPCMV genome 
in cell culture, it does provide selection for the recombinant virus. This could ultimately stabilize 
the modified GP25/26 locus in tissue culture; it is at least clear that the cassette does not initially 
inhibit the virus. This could be advantageous, as deletion of non-essential genes is common in 
GPCMV and the presence of gpIL-12B is likely to be detrimental to infection in vivo [Cui et al. 
2009].  
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Future experiments 
Once a recombinant GPCMV virus encoding gpIL-12B is successfully created and confirmed by 
sequencing, the expression of gpIL-12B must be confirmed using enzyme-linked immunosorbent 
assay (ELISA assays). The SV40 promoter is a medium-strength promoter [Yang et al. 2014]; 
reasonable levels of gpIL-12B expression are expected, but it is unknown what effect the 
genome environment of GPCMV might have on expression.  
Once gpIL-12B expression has been confirmed and quantified, experiments in live guinea pigs 
will be conducted to characterize the immune response to the recombinant virus in vivo. It is 
expected that gpIL-12B expression will enhance the T-cell response against GPCMV infection. 
This will be tested using an enzyme-linked immunosorbent spot (ELISPOT) assay to quantify 
the specific T-cell response to different GPCMV antigens. It is likely that the response to pp65 
will be enhanced, but it will be interesting to see if it enhances the T-cell response to other T-cell 
target antigens.  
 
Final Conclusion 
Though this study is still in progress, several goals have been achieved. A convenient and precise 
recombination system has been selected and tested, a shuttle vector containing a gene construct 
that does not impair GPCMV has been created, and gpIL-12B has been successfully cloned into 
that shuttle vector.  
When completed, this study may confirm the possibility of utilizing gpIL-12B as a GPCMV 
vaccine adjuvant to enhance the T-cell response to infection, which in turn will inform the 
pursuit of creating effective HCMV vaccines.  
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APPENDIX	  A	  
SUPPLEMENTARY	  FIGURES	  
Supplementary	  Figure	  1.	  Recombinant	  GP75	  knock	  out	  BAC.	  The	  GP75	  gene	  of	  GPCMV,	  which	  encodes	  the	  gH	  protein,	  was	  modified	  to	  contain	  a	  kanamycin	  resistance	  marker.	  In	  a	  shuttle	  vector,	  a	  portion	  of	  the	  gene	  was	  deleted	  using	  endogenous	  NruI	  and	  EcoRV	  sites	  within	  the	  gene.	  The	  kanamycin	  cassette	  was	  amplified	  as	  a	  NruI/EcoRV	  fragment	  by	  PCR	  and	  ligated	  into	  the	  digested	  vector.	  An	  EcoRI	  site	  was	  deleted	  and	  a	  HindIII	  site	  added,	  0.7	  kb	  from	  the	  start	  of	  the	  kanamycin	  cassette.	  The	  construct	  was	  recombined	  into	  the	  GPCMV	  BAC.	  
	  
Supplementary	  Figure	  2.	  Modified	  GP25/26	  gene	  construct.	  A	  portion	  of	  the	  GP25/26	  gene	  construct	  was	  amplified	  by	  PCR	  with	  the	  addition	  of	  an	  EcoRI	  site	  to	  the	  5’	  end	  and	  a	  
HindIII	  site	  to	  the	  3’	  end	  of	  the	  construct.	  These	  sites	  were	  used	  to	  clone	  the	  construct	  into	  the	  pUC19	  vector	  (Suppl.	  Fig.	  3),	  displacing	  the	  multiple	  cloning	  site	  (MCS)	  and	  creating	  the	  pGP2526	  vector.	  There	  is	  an	  endogenous	  BamHI	  site	  in	  the	  intergenic	  region.	  The	  construct	  is	  approximately	  1.3	  kb	  and	  the	  resulting	  modified	  vector	  is	  4	  kb.	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Supplementary	  Figure	  3.	  pUC19	  vector.	  Gene	  constructs	  were	  constructed	  in	  the	  pUC19	  vector	  (NEB).	  The	  vector	  was	  digested	  with	  EcoRI	  and	  HindIII	  and	  GP25/26	  construct	  ligated	  into	  the	  vector,	  displacing	  the	  MCS.	  The	  vector	  is	  approximately	  2.7	  kb	  in	  size.	  	  Source:	  New	  England	  Biolabs	  	  
Supplementary	  Figure	  4.	  pGP2526	  containing	  SV40	  promoter	  &	  polyadenylation	  
sequence.	  The	  SV40	  promoter,	  polyadenlyation	  signal,	  and	  all	  intervening	  sequences	  were	  digested	  out	  of	  the	  pSI	  vector	  (Suppl.	  Fig.	  5)	  as	  a	  BglII/BamHI	  fragment	  and	  ligated	  into	  the	  pGP2526	  vector	  BamHI	  site,	  destroying	  the	  upstream	  BamHI	  site.	  	  Restriction	  enzyme	  digestion	  with	  HindIII	  was	  used	  to	  confirm	  orientation	  of	  insertion.	  This	  construct	  was	  designated	  pGP2526pSI.	  The	  vector	  is	  approximately	  4.9	  kb	  in	  size.	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Supplementary	  Figure	  5.	  pSI	  vector.	  The	  pSI	  vector	  contains	  the	  SV40	  promoter	  and	  polyadenylation	  sequence,	  as	  well	  as	  the	  T7	  MCS	  and	  associated	  sequences.	  This	  construct	  was	  digested	  out	  of	  the	  vector	  as	  a	  BglII/BamHI	  fragment	  for	  ligation	  into	  the	  pGP2526	  vector.	  	  Source:	  Promega	  	  	  
	  
Supplementary	  Figure	  6.	  pLink2	  vector.	  The	  intron	  between	  the	  SV40	  promoter	  and	  polyadenylation	  sequence	  was	  not	  needed	  for	  our	  experiments	  and	  was	  causing	  instability	  in	  our	  gene	  construct,	  so	  it	  was	  digested	  out	  as	  a	  PstI/SalI	  fragment,	  which	  also	  removed	  most	  of	  the	  T7	  MCS.	  A	  modified	  linker	  designated	  Link2	  was	  ligated	  in	  place	  of	  the	  original	  MCS,	  containing	  the	  restriction	  sites	  described	  above,	  as	  well	  as	  the	  remaining	  sites	  from	  the	  T7	  MCS:	  AccI,	  SmaI,	  BstZ	  I,	  NotI.	  The	  vector	  size	  is	  approximately	  4.6	  kb.	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Supplementary	  Figure	  7.	  pLink2/Hyg	  Vector.	  A	  hygromycin	  resistance	  marker	  was	  ligated	  into	  the	  BamHI	  site	  of	  the	  pLink2	  vector.	  The	  hygromycin	  cassette	  (Genebridge)	  contains	  both	  a	  prokaryotic	  (Pgb2)	  and	  a	  eukaryotic	  promoter	  (PPGK)	  and	  was	  modified	  to	  contain	  end	  BamHI	  sites.	  EcoRI	  digestion	  was	  used	  to	  confirm	  orientation	  of	  insertion.	  The	  vector	  size	  is	  6.3	  kb.	  	  	  
	  
Supplementary	  Figure	  8.	  pLink2/IL-­‐12B	  vector.	  Guinea	  pig	  IL-­‐12B	  was	  synthesized	  by	  PCR	  and	  ligated	  into	  the	  pLink2	  vector	  as	  an	  XhoI	  fragment,	  disrupting	  the	  Link2	  MCS	  as	  shown	  above.	  EcoRI	  digestion	  was	  used	  to	  determine	  orientation	  of	  insertion.	  The	  vector	  size	  is	  5.6	  kb.	  	  	  	  
36	  
	  
Supplementary	  Figure	  9.	  pLink2/IL12BKMFRT	  vector.	  A	  kanamycin	  resistance	  marker	  was	  amplified	  from	  the	  pACYC177	  plasmid	  (NEB)	  as	  a	  BamHI	  fragment	  and	  ligated	  into	  the	  
BglII	  site	  of	  the	  vector,	  destroying	  the	  site.	  The	  cassette	  contains	  a	  prokaryotic	  promoter	  and	  flanking	  flippase	  recognition	  target	  (FRT)	  sites	  for	  use	  in	  FLP-­‐FRT	  recombination.	  
HindIII	  digestion	  was	  used	  to	  determine	  orientation	  of	  insertion.	  The	  vector	  size	  is	  6.6	  kb.	  	  	  
	  
Supplementary	  Figure	  10.	  Recombinant	  GPCMV	  BAC	  containing	  IL-­‐12B	  gene	  
construct.	  The	  construct	  in	  Suppl.	  Fig.	  9	  was	  recombined	  into	  a	  GPCMV	  BAC	  using	  the	  Red/ET	  recombination	  system	  (Genebridge)	  and	  a	  recombinase	  	  (Flp)	  was	  used	  to	  remove	  the	  kanamycin	  cassette,	  leaving	  only	  the	  FRT	  sequences	  flanking	  the	  gpIL-­‐12B	  gene.	  	  	  	  	  
	  
